scholarly article | Q13442814 |
P356 | DOI | 10.1136/BJOPHTHALMOL-2015-307299 |
P698 | PubMed publication ID | 26755642 |
P50 | author | Christian Prünte | Q55392643 |
Katja Hatz | Q99597154 | ||
P433 | issue | 10 | |
P921 | main subject | macular degeneration | Q27429789 |
P304 | page(s) | 1341-1345 | |
P577 | publication date | 2016-01-11 | |
P1433 | published in | British Journal of Ophthalmology | Q13443571 |
P1476 | title | Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration | |
P478 | volume | 100 |
Q33612736 | 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting |
Q37699709 | A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom |
Q57024766 | A simulation tool for better management of retinal services |
Q90723410 | Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison |
Q33840787 | Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases |
Q90100937 | Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment |
Q58754638 | Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group |
Q64967370 | Long-term incidence and timing of reactivation in patients with type 3 neovascularization after initial treatment. |
Q58775553 | Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect |
Q33740174 | Resource Use and Real-World Outcomes for Ranibizumab Treat and Extend for Neovascular Age-Related Macular Degeneration in the UK: Interim Results from TERRA |
Search more.